SlideShare a Scribd company logo
swiftbiosci.com
APAC Distributor Training Series:
Swift Product for Cancer Study
Jan 2021
Mengmeng Lin (mlin@swiftbio.com)
swiftbiosci.com
Swift Library Prep Overview: IP families
Adaptase
2S/Amplicon
Normalase
Accel-NGS Methyl-Seq
For quant-free
library pooling
Accel-Amplicon or
SNAP Amplicon
(Single-tube multiplex PCR)
Swift 2S Turbo
Accel-NGS 2S
(PCR-free, Plus, Hyb)
Accel-NGS 1S
Accel-NGS
For Ion Torrent
Adaptase Module
(single cell methyl)
Accel-NGS XL
for PacBio
Swift RNA
Swift Rapid RNA
Done:
7th Dec Swift Product for Metagenomics Study
21st Dec Swift Product for Virus Study
More Distributor Training:
Feb 2021 Swift Product for Very Specific Application
Not covered product
Swift 2S Sonic
swiftbiosci.com
Today’s Topic
Cancer Study
Genomic
Sequencing
RNA
Sequencing
Swift RNA library kit
Swift Rapid RNA library kit
After this training session:
• Able to know benefit of choosing each Swift DNA/ RNA library prep kit for cancer study
• Able to know why choose amplicon workflow and why Swift amplicon product
Amplicon
Panel
Hyb Capture
Swift DNA library prep kit+
Swift hyb capture panel / 3rd party panel
• Accel-NGS 2S kit
• Accel-NGS 1S kit
• 2S Turbo
• 2S Sonic
DNA
Methylation
WGS
Swift gene/cancer-
based panel
Somatic/germline
mutation detection
Fusion gene
Alternative splicing
RNA expression
Rare & novel transcripts
Disease-associate SNV
…
Hyb Capture WGBS
Swift Methyl-seq Kit+
Arbor Bio myBaits MethylCap
Swift Methyl-seq Kit
Hyb Capture RNA-seq
Swift RNA library kit or
Swift Rapid RNA library kit
+
Swift hyb capture panel / 3rd
party panel
swiftbiosci.com
Type of Mutation in Cancer
(1) Inherited (blood spot, whole blood, buccal swab, agricultural)
An inherited gene mutation is present in the egg or sperm that formed the
child.
Germline mutation (because the cells that develop into eggs and sperm
are called germ cells) or hereditary.
Inherited mutations are thought to be a direct cause of only a small fraction
of cancers.
Germline calling where VAF = 50% or 100%
(2) Acquired (Fresh frozen tissue, FFPE, cfDNA/ctDNA)
An acquired mutation is not present in the zygote, but is acquired some
time later in life. Somatic mutation
Type:
- Substitutions of one base by another
- Insertions or deletions of small or large segment of DNA
- Rearrangement (DNA has been broken and then rejoined to a DNA segment
from elsewhere in the genome)
- Copy number increase (increases from the two copies present in the normal
diploid genome, also know as gene amplification)
- Copy number reductions
https://www.cancer.org/cancer/cancer-causes/genetics/genes-and-cancer/gene-changes.html
Landscape of somatic mutations present in a single
cancer genome
Nature. 2009 April 9; 458(7239)
swiftbiosci.com
Variant classification
Ensembl Variation
https://m.ensembl.org/info/genome/variation/prediction/classification.html
SV
swiftbiosci.com
Genetic
Risk
Early
Detection
Patient
Stratification
Disease
Staging
Treatment
Options
Outcomes
Relapse
Monitoring
Birth Death
Treatment
Natural History of Disease Clinical Care
Early screening for
germline mutation
NGS for Cancer Studies
Somatic mutation
or biomarker detection
“Personalized Medicine”
Molecular diagnostic
Target therapy or drug
resistance test
swiftbiosci.com
https://www.illumina.com/science/customer-stories/icommunity-customer-interviews-case-studies/patton-jennings-tan-yan-ngs-oncology.html
Hyb workflow:
Swift DNA or RNA library prep kit
+ Swift or 3rd party capture panel
Swift Amplicon:
Accel or SNAP version
WGS:
Swift DNA library prep kit
swiftbiosci.com
2S Turbo 2S Sonic
Differentiators: Enzymatic fragmentation, fast and easy prep,
competitive price point, flexible adapter options
Key Applications: WGS (complex and/or small genomes), Targeted
(exome, panels), Genotyping by NGS, CNVs, Metagenomics
Target Customer: Production scale laboratories, such as: large PI,
core lab and service providers
Sample Types: gDNA, high quality FFPE, RNA (1st strand cDNA)
Input Range: 1-250 human or microbial (3rd party adapters),
50-250ng human or 1-250ng microbial (Swift adapter)
Differentiators: Mechanical Shearing, fast and easy prep, competitive
price point, flexible adapter options
Key Applications: WGS (complex and/or small genomes), Targeted
(exome, panels), Genotyping by NGS, CNVs, Metagenomics
Target Customer: Production scale laboratories, such as: large PI, core
lab and service providers
Sample Types: gDNA, high quality FFPE, cfDNA
Input Range: 1ng-1ug human or microbial
1S Plus Adaptase 2S (Plus, Hyb, PCR-Free)
Differentiators: ssDNA or ss/dsDNA mix, nicked DNA, RNA (1st
strand cDNA), viral genome, highly degraded/ancient DNA, short
fragments >40 bp…WHEN 2S FALLS SHORT!
Key Applications: WGS/ Hyb, ChIP-Seq, Metagenomics
Target Segment: Infectious Disease, Agriculture,
Archeology/Museum, Forensics, Biotechnology, Biopharma, Academic
and Government Labs
Sample Types: highly degraded FFPE, Ancient DNA, degraded
cfDNA, Very Low Input ChIP samples
Input Range: >10pg
Differentiators: Mechanical Shearing, degraded or dilute
samples such as FFPE and cfDNA
Key Applications: WGS (complex and/or small genomes), Targeted
(exome, panels), ChIP-Seq, low frequency variant detection, CNV
Target Customer:
Sample Types: gDNA, FFPE, cfDNA, RNA (1st strand cDNA) amplicons
Input Range: >10 pg (w/ PCR)
10 ng (cfDNA PCR-Free)
100 ng (gDNA PCR-Free)
Swift Product Selection and Positioning Guide
swiftbiosci.com
Turbo Turbo
New!! Swift 2S Turbo DNA Library Kits
for Illumina® platforms
With Enzymatic Shearing
Tissue or Blood Sample Type for Cancer Study
swiftbiosci.com
Custom adapter guide(IDT): https://sfvideo.blob.core.windows.net/sitefinity/docs/default-source/supplementary-product-info/idt-custom-ngs-adapters-product-sheet.pdf?sfvrsn=45d71f07_6
Minimal enzymatic incubation
&
purification steps
Indexing PCR
Time varies
Optional PCR
Terminal primers (included)
to increase library yield
Time varies
Ligation
3’ and 5’ ligation of P7 and p5
full-length adapters(Your choice of adapter)
truncated adapters
Flexible
✔️1-250 human
or microbial
✔️ PCR-free
Flexible
New! Swift 2S Turbo V2 DNA Library Kits will
launch soon
Choice of Kits: Standard & flexible
Standard
✔️50-250 human
or 1-250ng microbial
✘ PCR-free
Targeted sequencing
2S Turbo DNA library kit
swiftbiosci.com
Swift 2S Turbo Library Kit was
evaluated for enrichment using Swift
Exome and Pan-Cancer Hyb Panels.
Comprehensive target coverage and
high complexity was observed with
multiple sample types, input
quantities, and platforms. Coverage
uniformity and complexity was higher
with low input Turbo libraries
compared to competitors (see
highlighted region of table).
Turbo’s efficient library provide
more data at low input !
*FFPE and HD200 sample integrity quantified by qPCR using the Swift ALU repeat assay provide with the Swift library prep kits, 0.34 ratio obtained for both samples.
Benchmarking: Hyb Capture Better Coverage
Uniformity with low input
swiftbiosci.com
*FFPE and HD200 sample inputs quantified via qPCR of smaller ALU 115 repeat.
+Based on 247/115 ALU repeat fragment ratios
Sample
Integrity+
Input
(ng)*
%Duplicates
Mean Bait
Coverage
%Covered
≥ 20X
%Covered
≥ 50X
%Covered
≥ 100X
% Bases On-Target
0.24 25 6 176X 99.5 98.3 90.7 73.8
0.26 25 8 173X 99.6 98.5 94.6 74.9
0.34 24 4 163X 99.1 98.1 89.7 70.3
0.34 79 6 151X 99.4 98.5 90.2 69.6
Uniform Coverage for Somatic Mutation Detection
Targeted Sequencing of FFPE using Swift Exome Panel (MiSeq Run)
Sequencing metrics of FFPE samples match control samples
(e.g. NA12878 % bases on target = 68-75%).
swiftbiosci.com
Swift Deceleration Module to control fragmentation
reaction time for automation
15 uL
10 uL
3 uL
1.5 uL
5 uL
Reagent DE
into frag
reaction
Fragment
Mode (bp)
1.5 uL 382
3 uL 434
5 uL 467
10 uL 600
15 uL 750
Automation Request
• Slow fragmentation to 15 min for 350-400bp
• Prepare reaction at room temp
• Sample placed on cycler 10 min after adding fragmentation mix
Actions
• Tested various volumes of Reagent DE in fragmentation reaction
• Ensured reproducible fragmentation, and no influence in Exome Capture
Will be added to Turbo protocol
☺︎ large insert size (>350bp) (ie, metagenomics)
☺︎ Automation
☺︎ SOP
☺︎ Similar fragment time for various condition of degraded
samples
swiftbiosci.com
Accel-NGS® 2S DNA Library Kits
With Mechanical Shearing
For balanced coverage of dsDNA, even at low input
swiftbiosci.com
Swift 2S: Superior Data Quality
High adapter ligation efficiency
 Unique 3’ end repair that efficiently converts all 3’-P into 3’-OH and at
the same time prevents chimera formation
 Unique 5’ end repair that replaces bases damaged by physical
shearing
 No A-tailing
 No adapter titration for low inputs maintains high ligation efficiency
 Very low adapter dimers
 Introduces Molecular ID tags (MIDs)
Best Data Quality
 WGS and exome sequencing
 Metagenomic sequencing (ultra-low inputs <1ng down to 10 pg)
 ChIP-Seq (including ultra-low inputs down to 10 pg)
 FFPE and cfDNA/ctDNA (>10 ng PCR-Free)
 HiC-Seq (as low as 5000 cells)
FFPE Sample
Accel-NGS® 2S DNA Library Kits
swiftbiosci.com
2S Hyb Performance with Fixed Samples
of Various Fixation Times and Input Levels
Fixation Time Course with the Pan-Cancer Panel
Accel-NGS® 2S Hyb libraries were constructed with 100, 10, and 1 ng of DNA. DNA extracted from the same
normal kidney sample which had either been fresh-frozen or fixed for 6, 24, or 48 hours before being paraffin-
embedded. Amplified libraries were enriched with the IDT xGen® Pan-Cancer Panel. The xGen Pan-Cancer Panel is
0.9Mb and all samples were normalized to 0.6Mb reads.
INPUT
QUANTITY
SAMPLE
TYPE
%
ALIGNED
%
DUPLICATION
MEAN BAIT
COVERAGE
% COVERED
> 1X
% COVERED
> 20X
% BASES ON
TARGET
100 ng
Frozen 96 1 42X 99 91 80
6 Hr. Fix 96 1 43X 99 93 81
24 Hr. Fix 97 1 44X 99 93 82
48 Hr. Fix 97 1 45X 99 88 82
10 ng
Frozen 96 3 42X 99 90 80
6 Hr. Fix 96 5 41X 99 92 80
24 Hr. Fix 97 4 42X 99 93 81
48 Hr. Fix 97 8 42X 99 86 81
1 ng
Frozen 95 18 33X 99 85 77
6 Hr. Fix 94 32 26X 99 77 74
24 Hr. Fix 95 31 27X 100 79 76
48 Hr. Fix 95 44 22X 99 53 73
swiftbiosci.com
Choice of Index- MID
Enable accurate de-duplication from single read sequencing,
and distinguishing PCR duplicates from fragmentation and
strand duplicates.
Posters
9 base
N sequence
6 or 8 base
swiftbiosci.com
Choice of Index- MID
Only 1x coverage
was retained post-
deduplication
increase in data
retention up to 6x
coverage post
deduplication.
swiftbiosci.com
MID Enable Ultra-Low Frequency Variant
Detection
cfDNA was extracted from blood of four individuals
with unique genetic background and Coriell gDNA
samples from different genetic backgrounds were
obtained. To determine the effect of MIDs on low
frequency variant calling, sample spike-ins were
performed at 1% or 0.5% frequency into 10 ng
cfDNA or 100 ng gDNA. Libraries were prepared
with the Swift 2S Hyb kit with MIDs, enriched with
the Swift Pan-Cancer Hyb Panel , and sequenced
on an Illumina HiSeq ® to a minimum of 8000x
coverage. A consensus sequence was generated
for each MID family (BMFtools) and data were
analyzed for homozygous SNPs present in the
spike-in sample only. 6/6 known variants were
present in all three 1% cfDNA samples and 27/27
known variants were present in both 1% and 0.5%
gDNA samples depicting the power of MIDs for low
frequency variant calling.
swiftbiosci.com
Patient- derived xenografts (PDX)
CTC-derived xenografts (CDX)
Cancer Discov; 6(3); 286–99.
Cancer Research UK Manchester Institute
WES + multiplex PCR panel, long term monitoring
response of sequential targeted, immuno- and
chemotherapy of one melanoma patient.
10-25 ng cfDNA WES) swift 2S
Cancer Research UK Manchester Institute
• 214 patients (364 samples) with stage II, III, IV
melanoma
• 13ng cfDNA (WES on Miseq) swift 2S )
• Application:
Facilitate individualized treatment decisions for
patients with advanced melanoma
Publication for Clinical-based
swiftbiosci.com
Part A (100 patients,22 tumor type) Part B (450
patients)
Workflow establishment & test its feasibility
Workflow for ctDNA test:
4x 10mL Streck
↓
Manual purification: QIAmp Circulating Nucleic Acid Kit (Qiagen)
Automation purification: :QIAsymphony (Qiagen)
↓
0.5 to 25 ng ctDNA for Accel-NGS 2S DNA Library Kits
↓
SureSelectXT Reagent Kits (Agilent) 641-gene panel, 2.1Mb
↓
Illumina NextSeq 500, 2 × 150 bp
TARGET
(Tumor chARacterisation to Guide Experiment Target therapy)
Aim:
Use ctDNA to identify clinically actionable mutations in early
phase clinical trail patients with a range of advanced-stage
cancers.
Publication for Clinical-based
swiftbiosci.com
Accel 2S Plus – Best Coverage and Superior Variant Detection in ccfDNA
• Prostate cancer plasma sample
• Prepared 10ng ccfDNA with Accel 2S Plus,
along with 3 other library prep kits.
• Sequenced on Illumina HiSeqX
(2 x 150bp PE)
• Analyzed CNV, SNV and Indels
• Accel 2S Plus kit detected more variants
and specific SNVs, INDELs and CNVs.
• Accel 2S Plus provided the best coverage
Mauger, F., et al. Comparison of commercially available whole-genome sequencing kits for variant detection..., Sci Rep 10, 6190 (2020)
Publication for Methodology Comparison
swiftbiosci.com
Accel-NGS® 1S Plus DNA Library Kit
For Difficult-to-Process Samples Including Damaged,
Denatured, or ssDNA
swiftbiosci.com
Accel-NGS® 1S Plus Specifications
• Broad input range from 10 pg to 250 ng
• Adapt strands of DNA ≥ 40 bp long
• Simple, 2-hour protocol
• Offered for Ion Torrent™ and Illumina
®
• No end polishing step
Features
• Capture previously unattainable sequences
• Process more samples per day
• Use platform of choice
• Preserve input fragmentation patterns for
precise mapping of DNA insert ends
Benefits
Ion Torrent is a trademark of Thermo Fisher Scientific. Illumina is a registered trademark of Illumina, Inc.
Adaptase tail
Truncated P7 adapter
ssDNA
swiftbiosci.com
Cancer Research UK Cambridge Institute
200 patients (18 different cancer types)
65 plasma samples
90–150 bp
180–220 bp
250–320 bp
High ctDNA: breast, ovarian, lung, melanoma, colorectal, and cholangiocarcinoma
Low ctDNA: glioma, renal, pancreatic, and bladder cancers.
Mutant ctDNA is generally more fragmented than non-
mutant cfDNA (19 cancer patients)
Mutant DNA in plasma of patients with advanced cancer is consistently
shorter than predicted mono-, and di-nucleosomal DNA fragment lengths
swiftbiosci.com
6.4倍富集
4倍富集
Longitudinal plasma samples of a colorectal cancer patient
Detect tumor progression 60 and 87 days before by
imaging or unselected t-MAD analysis.
Improve the detection of response or disease progression
60 days
87 days
swiftbiosci.com
AUC = 0.97
(sens: 90% & spec:98%)
AUC = 0.64
4.19X
SNVs
Conclusion:Size selection of shorter plasma DNA fragments enriches ctDNA and assists in the identification of a
greater number of genomic alterations with both targeted and untargeted sequencing at minimal additional cost.
Increased number of mutations detected in plasma
(samples from 6 patients with HGSOC)
swiftbiosci.com
https://www.illumina.com/science/customer-stories/icommunity-customer-interviews-case-studies/patton-jennings-tan-yan-ngs-oncology.html
Hyb workflow:
Swift DNA or RNA library prep kit
+ Swift or 3rd party capture panel
Swift Amplicon:
Accel or SNAP version
WGS:
Swift DNA library prep kit
swiftbiosci.com
Swift RNA Library Kits
swiftbiosci.com
Feature Specification Benefit
Input Quantity
10 ng – 1 g total RNA
100 pg – 100 ng mRNA
Supports a Wide Range
Consistent Library Output
RNA Types
Supported
Poly(A)-enriched mRNA
Ribodepleted RNA
Total RNA
Supports Most RNA
Applications
Technology
Adaptase® tailing and ligation
of 1st strand cDNA
No 2nd Strand cDNA
No Adapter Titration
Lowest Dimers & Duplicates
Maintains Strandedness,
High Mapping & Detection
Time 4.5 hours
Save 1 hour vs. NEBNext®
Half the time of TruSeq®
Kit Reaction
Sizes
24 • 96 Evaluation and Adoption
Indexing
Options
Single • Combinatorial Dual
Unique Dual • Normalase
Flexible to Sequencers,
Workflows and Applications
Multiplexing
Capability
Up to 768 libraries Save Sequencing Costs
Automation
Compatible with Liquid
Handlers
Custom Packaging Available
Adopt at Scale
Fast
Lowest Inputs
Low Cost
Feature Specification Benefit
Input Quantity
100 ng – 1 g total RNA
5 ng – 100 ng mRNA
Supports a Wide Range
RNA Types
Supported
Poly(A)-enriched mRNA
Ribodepleted RNA
Total RNA
Supports Most RNA
Applications
Technology
Adaptase® tailing and ligation
of 1st strand cDNA
High Strandedness
No 2nd Strand cDNA
No Adapter Titration
Time 3.5 hours Fastest on Market
Kit Reaction
Sizes
24 • 96 Evaluation and Adoption
Indexing
Options
Single • Combinatorial Dual
Unique Dual • Normalase
Flexible to Sequencers,
Workflows and Applications
Multiplexing
Capability
Up to 768 libraries Save Sequencing Costs
Automation
Compatible with Liquid
Handlers
Custom Packaging Available
Adopt at Scale
Fastest
Lowest Cost
Swift Rapid RNA Library Kit
Accelerate Your RNA-Seq Discovery
Swift RNA Library Kit
Deepen Your RNA-Seq Discovery
swiftbiosci.com
Why not Poly(A)?
 10ng RNA for Swift RNA Library Kit
 100ng RNA for Swift Rapid RNA Library Kit
 100pg RNA for Swift RNA Library Kit
 5ng RNA for Swift Rapid RNA Library Kit
swiftbiosci.com
Ribodepletion VS. Capture
Sample
Library
yield
(nM)
STAR
mapping
rate (%)
Genes
detected
Exonic
rate (%)
rRNA
rate (%)
ERCC
(R2
)
UHR RNA
44.2 86.2 17,132 46.0 3.4 0.94
33.6 87.5 17,180 46.2 3.2 0.92
FFPE
Sample 1
14.0 83.6 15,095 22.0 6.7 0.91
19.8 85.7 15,112 21.2 6.0 0.92
FFPE
Sample 2
24.9 84.2 15,274 24.6 4.8 0.92
23.9 85.5 15,325 25.7 4.5 0.94
UHR
FFPE
Sample 1
FFPE
Sample 2
UHR
Ribo-
depleted
UHR FFPE
Sample 1
FFPE
Sample 2
Sample
Library
yield
(ng/uL)
STAR
mapping
rate (%)
Genes
detected
Exonic
rate (%)
rRNA
rate
(%)
Selected
bases
(%)
UHR
RNA
82 89.6 17,758 91.2 1.3 96.7
FFPE
Sample 1
93 88.8 17,009 89.2 0.9 96.5
FFPE
Sample 2
73 87.9 17,024 88.1 1.0 95.8
Sample
Library
yield
(ng/uL)
STAR
mapping
rate (%)
Genes
detected
Exonic
rate (%)
rRNA
rate
(%)
Selected
bases
(%)
FFPE
Sample 3
23.0 89.4 16,089 87.4 1.5 95.1
FFPE
Sample 4
54.0 88.0 16,065 88.7 1.3 95.6
FFPE
Sample 5
33.4 87.5 15,653 87.6 1.3 94.6
FFPE
Sample 6
56.0 87.6 16,246 88.4 1.2 95.4
DV200 = 60
DV200 = 61
DV200 = 54
DV200 = 54
Ribodepletion (100ng of total RNA input)
Capture (100ng of total RNA input)
Capture (10ng of total RNA input)
https://swiftbiosci.com/wp-content/uploads/2020/01/APP-004-THE-SWIFT-RNA-LIBRARY-KIT-OPTIMIZES-RNA-SEQ-DATA-QUALITY-AND-COSTS-FOR-FFPE-
SAMPLES-Rev-1.pdf
swiftbiosci.com
Capture Workflow for Lower Inputs
Swift RNA on FFPE samples
100 pg total RNA
20 PCR cycles
Yields > 20 nM
1:10 dilution loaded on Bioanalyzer HS DNA chip
10 ng total RNA
16 PCR cycles
Yields > 100 nM
HER2- Sample 1
DV200 = 54
HER2+ Sample 4
DV200 = 61
HER2- Sample 3
DV200 = 54
Confidential
HER2- Sample 1
DV200 = 54
HER2+ Sample 4
DV200 = 61 HER2- Sample 3
DV200 = 54
swiftbiosci.com
HER2-
Sample 4
DV200 = 73
327 bp
93 ng/uL
HER2+
Sample 6
DV200 = 48
296 bp
73 ng/uL
100 ng FFPE RNA input directly into Swift library prep kits
1:10 dilution loaded on Bioanalyzer HS DNA chip
Library details:
• 100 ng total RNA
• 2 min @ 94 C adjusted
fragmentation time
• Relaxed 1.8X SPRIs
throughout
• 12 PCR cycles
HER2-
Sample 4
DV200 = 73
318 bp
58 ng/uL
HER2+
Sample 6
DV200 = 48
282 bp
66 ng/uL
Capture Workflow for Both Swift Kits
Swift RNA& Rapid RNA Library Kits on FFPE RNA (pre-hyb)
Swift RNA Swift Rapid RNA
swiftbiosci.com
Today’s Topic
Cancer Study
Genomic
Sequencing
RNA
Sequencing
Swift RNA library kit
Swift Rapid RNA library kit
After this training session:
• Able to know benefit of choosing each Swift DNA/ RNA library prep kit for cancer study
• Able to know why choose amplicon workflow and why Swift amplicon product
Amplicon
Panel
Hyb Capture
Swift DNA library prep kit+
Swift hyb capture panel / 3rd party panel
• Accel-NGS 2S kit
• Accel-NGS 1S kit
• 2S Turbo
• 2S Sonic
DNA
Methylation
WGS
Swift gene/cancer-
based panel
Somatic/germline
mutation detection
Fusion gene
Alternative splicing
RNA expression
Rare & novel transcripts
Disease-associate SNV
…
Hyb Capture WGBS
Swift Methyl-seq Kit+
Arbor Bio myBaits MethylCap
Swift Methyl-seq Kit
Hyb Capture RNA-seq
Swift RNA library kit or
Swift Rapid RNA library kit
+
Swift hyb capture panel / 3rd
party panel
swiftbiosci.com
Accel-NGS® Methyl-Seq
DNA Library Kits
Library Preparation for Bisulfite-Converted DNA
swiftbiosci.com
Adaptase-based (1S, Methyl, Module, RNA)
U U U
U U U
U U U
Powered by Swift’s Adaptase®
Technology
•Single-stranded tailing and ligation
•Template-independent reaction
•>90% efficiency
•US Patent 9,896,709
•Underlying technology of Swift Methyl-Seq and
Single Cell Methyl (Adaptase Module) and 1S
Plus Library Kit
Benefits to Methyl-seq
• >40bp retention
• Lower input requirement
• Able to use ss&dsDNA as library prep template
swiftbiosci.com
PreBS PostBS
2% amplifiable
fraction
- High input
- Low yield
- High dup%
- Low diversity%
PBAT
- Uneven coverage
- High dup%
- Low diversity
Target towards
CpGs
swiftbiosci.com
4841 participants
CCGA Study
PATHFINDER
Study
STRIVE Study SUMMIT Study
Current Status Follow-up (>5 year) Enroll Follow-up (5 year) Enrolling
Actual/Expected
Enrollment
15254 participants 6,200 participants
99481 participants
(women)
50,000 participants
Sample Type Blood and tumor tissue A single blood draw Blood Blood
Time Perspective/
Purpose
Prospective Screening Prospective Prospective
Actual Study Start
Date
August 2016 December 2019 February 2017 April 2019
Estimated
Completion
March 2024 June 2021 May 2025 August 2030
https://grail.com/clinical-studies/
On-going Clinical Trials
swiftbiosci.com
https://doi.org/10.1016/j.annonc.2020.02.011
4841 participants
Annals of Oncology
>50 Cancer type
Adrenal (cortical carcinoma and neuroendocrine),
ampulla of Vater, anus, appendix, bone, brain and spinal
cord, breast, cervical lymph nodes and unknown primary
tumors of the head and neck, cervix uteri, colon and
rectum, corpus uteri…
STRIVE study
Training set + 1587
Validation + 615
6689 total
WGBS vs. WGS vs. target sequencing
Population-level screening
swiftbiosci.com
Step 5
Targeted Enrichment
Sequenced fragments are
associated back to regions
of interest
Step 6
Median depth: 113 million
median unique on-target depth: 139X
150bp PE sequencing, NovaSeq
Step 1
CCGA :8 tubes of 10mL whole blood
STRIVE: 4 tubes of 10mL whole blood
(Streck)
Centrifuge:<5days,median <2 days
Step 4
Swift Methyl-seq kit for
library preparation
WGBS; 30X depth
(n=3,508)
Twist panel (17.2Mb)
1,116,720 CpG
(~10 regions)
7.5Mb hypomethylated sites
7.4Mb hypermethylated sites
2.3Mb target both
Step 3
Bisulfite conversion:
EZ-96 DNA Methylation Kit (Zymo)
≥0.99 conversation rate
Step 2
10mL plasma, 75ng cfDNA
Manual: QIAamp Circulating Nucleic Acid kit
Automation: MagMax kit (ThermoFisher)
Enroll population: progressing advanced cancers(2011-
2016)
Sample collection: 1-4mLplasma (ETDA tube
Purification: QIAamp Circulating Nucleic Acid kit (4.5-30ng,
avg 21.1ng)
BS: EZ DNA Methylation-Lightning Kit (Zymo Research)
Library Prep: Accel-NGS Methyl- Seq DNA Library Kit
(Swift Biosciences)
Hyb Capture: llumina TruSight Rapid Capture Kit
Sequencing: Illumina HiSeq 2500 (2x100 cycle)
~10,000x mean target coverage
Targeted Methylation Sequencing of Plasma Cell-free DNA for
Cancer Detection and Classification
MD Anderson Cancer Center, Phase I Clinical Trials
9223 CpG sites, 32 cancer
type
( hypermethylated in tumors )
Liu. L, F.Janku, et. Al, 2018. Annals of Oncology
37 samples from late phase of CRC
Cutoff 7.52
Sens: 94.4%
Spe: 100%
Performance Evaluation
Publication for Clinical-based
(A) Patients on therapy had lower
methylation rates
(B) Patients with lower methylation rates
(blue) had longer survival rates
(C) Patients with lower methylation rates
had longer time to treatment failure
(D) Positive correlation between
methylation score and best RECIS
(response) score
Liu. L, F.Janku, et. Al, 2018. Annals of Oncology
68 patients off therapy (83.8% sens)
14 patients on therapy (50% sens)
OS
Off-therapy
TTF
55 patients
10.4 months
4.4 months
1.6 months
2.8 months
Clinical validation(78 patients with advanced colorectal
cancer, non-small-cell lung cancer (NSCLC), breast cancer or
melanoma
Targeted Methylation Sequencing of Plasma Cell-free DNA for Cancer
Detection and Classification
MD Anderson Cancer Center, Phase I Clinical Trials
Publication for Clinical-based
swiftbiosci.com
Publication for Research-based
A large integrated study of WGS, WGBS and whole-transcriptome, first study to look at comprehensive methylation
landscape in metastatic prostate cancer.
Observed that 22% of tumors exhibited a novel epigenomic subtype associated with hypermethylation and somatic mutations
in these four driver genes: TET2, DNMT3B, and BRAF.
swiftbiosci.com
Publication for Research-based
Wu et al., 2020, The Journal of Clinical Investigation
Characterize the plasma methylome in mCRPC and identify
prostate cancer–specific methylation signatures.
University College London Cancer Institute
swiftbiosci.com
Publication for Methodology Development
Uses the methylation profiles of adjacent CpG sites on an individual read to
accurately identify the tumor cfDNA fraction in plasma.
CancerDetector-generated tumor burden percentages correlated well with
tumor size (0.87) and can thus be used to monitor disease progression and
treatment.
This publication describes CancerLocator, a method that
simultaneously infers the proportion and tissue of origin of ctDNA in a
blood sample using WGBS.
CancerLocator performance was evaluated on both simulated data and
real data, and compared to that of 2 established multi-class
classification methods
swiftbiosci.com
Publication for Methodology Comparison
NanyangTechnological University, Singapore;UCL
The Accel-NGS Methyl-Seq kit had the
best GC coverage across both genomes
Accel-NGS Methyl-Seq
TruSeq Methyl-Seq
NEBNext Ultra
SPLAT (home brew)
Accel-NGS Methyl-Seq
TruSeq Methyl-Seq
QIAseq Methyl Library kit
swiftbiosci.com
Swift Solution for Target Methyl Study
Swift Methyl-Seq + Arbor Bio myBaits MethylCap
+
https://swiftbiosci.com/wp-content/uploads/2020/10/AppNote_Arbor-Swift_MethylSeq_2020-3.pdf
Webinar: https://www.youtube.com/watch?v=iZydUU-DZgI
swiftbiosci.com
https://www.illumina.com/science/customer-stories/icommunity-customer-interviews-case-studies/patton-jennings-tan-yan-ngs-oncology.html
Hyb workflow:
Swift DNA or RNA library prep kit
+ Swift or 3rd party capture panel
Swift Amplicon:
Accel or SNAP version
WGS:
Swift DNA library prep kit
swiftbiosci.com
Accel-Amplicon Panels™
Normalase™ Amplicon Panels (SNAP)
swiftbiosci.com
• Consists of individually synthesized and quality controlled
probes that have been validated to provide the highest level
of performance
• ~9-hour workflow
• 500 ng per library, up to 12-plex
• 150-350 bp fragment size
• Customizable
Swift Hybridization Capture Kits
Accel-Amplicon™ Panels
• Accel-Amplicon and SNAP Panels combine the
easiest, fastest workflow with flexible content to
accelerate your variant discovery and screening.
Simply leverage our pre-designed, validated core
content and add your own targets.
• ~2-hour (Accel)/ ~3-hour (SNAP) workflow
• 10 ng input sample
• Average amplicon size ~130-140bp
• Customizable
Panel size
Gene Panels
(<50genes)
Gene Panels
(>50genes)
DAR
(Disease associate regions)
Exome
20-30%Probes
70-80%Amplicon
50%Probes
50%Amplicon
70-80%Probes
20-30%Amplicon
80-90%Probes
10-20%Amplicons
swiftbiosci.com
Swift Amplicon NGS Panels
Format
• Core + customizable gene content
• Single-tube, highly multiplexed assay
• DNA to library in 2 hours for Accel-amplicon
3 hours for SNAP panel workflow
• 10 ng input of cfDNA or FFPE DNA
• Illumina®, Ion Torrent™ for Accel-amplicon
Only Illumina® for SNAP Panels
Performance
• Limit of detection of 1% VAF
• On-target > 90%
• Coverage uniformity > 90%
• Compatible with cfDNA and FFPE
• Supports limited amounts of DNA
• Cost-effective
Accel-amplicon SNAP amplicon
swiftbiosci.com
• Low uniformity and lack of coverage
• Multiple primer pools increase the input requirement
• You need large contiguous stretches of DNA in order to make library
• Inflexibility to add primers to increase the size of the panel
• Low library complexity
• Inability to cover entire coding regions
Traditional two-primer strategy
swiftbiosci.com
Competitors of Two-Primes Panel
https://www.youtube.com/watch?v=D3Dv7QHpLcs
swiftbiosci.com
• OVERLAPPING AMPLICONS IN A
SINGLE REACTION
• Low total input
• Few reagents, less time
• Fast workflow
• ~2hrs or 3hrs
• Accel-Amplicon™ or SNAP Amplicon panels
may be used to interrogate the following types
of variants in samples:
- SNV
- Insertions and deletions
- CNV
Why are Swift Amplicon Products Special?
Multiplex PCR with
overlapping target
specific-primers
Swift Panel Design base on OncoKB and market
research
Included
OncoKB Introduction
https://www.youtube.com/watch?v=XqoKrrm2Boc&feature=youtu.be
Swift used:
FDA-recognized biomarkers
Standard of care biomarkers
Available Panels
56G and 57G Pan-Cancer Profiling
EGFR Pathway (KRAS/NRAS/BRAF)
BRCA1 and BRCA2
BRCA1, BRCA2 and PALB2
TP53 (all exons)
CFTR (all exons, UTRs, some introns)
Sample_ID
Colorectal Cancer
Lynch Syndrome
Myeloid Disease
Lung Cancer
Gene-Based Disease-Based
swiftbiosci.com
• ERASE-Seq (Elimination of Recurrent Artifacts and Stochastic Errors) functions by
quantitatively modeling the background error profile of normal controls that have
gone through the library prep and sequencing process in order to establish the
inherent noise distribution for each possible variant
• ERASE-Seq delivers superior detection sensitivity to 0.05% allele frequency (AF),
with a false positive rate 10-100X lower than leading molecular barcode.
Benefits:
• Superior sensitivity and 10-100X fewer false positives than molecular barcodes (UMIs)
• Excels in the 0.05%-0.5% AF range where molecular barcodes struggle
• Any targeted panel can be adapted easily to ERASE-Seq with software validation- and no barcodes needed
• Provides similar detection performance to digital PCR, but can test for thousands of variants per test
• Validated in numerous sequencing labs globally
swiftbiosci.com
Swift Amplicon HS Panels
Confident Detection of Low Frequency Variants
in Liquid Biopsy Sequencing
swiftbiosci.com
Swift Amplicon HS – Features, Benefits, Pricing
Features and Benefits
• Sensitive and Specific
Robustly detect SNVs and indels down to 0.2%
• Compatible with cfDNA
Amplifies from 10-20 ng of cfDNA
• Fast workflow, high quality data
From DNA to Illumina® libraries within 3 hours
• Paired Data Analysis Tools
Cloud-based via Genialis or open-source
Ordering Information
Swift Amplicon HS EGFR Panel, Cat. No. HS-51024, 24 rxns
A focused cfDNA-compatible panel covering clinically-relevant oncology
hotspots including EGFR T790, KRAS G12/G13,NRAS Q61 and BRAF V600
swiftbiosci.com
Turbo flexible
+ IDT Probes
10-100 amplicons/tube
15-1,500 amplicons/tube
Using a custom panel targeting 30 hotspot amplicons in
these four genes, NGS was performed on cell-free DNA
extracted from plasma at the time of hysterectomy and the
matching tumor DNA from 48 patients with endometrioid
endometrial carcinomas.
These results demonstrate that mutations in genes
relevant to endometrial cancer can be identified in the
peripheral blood of patients at the time of surgery
swiftbiosci.com
Conclusion: ctDNA could be a powerful tool for therapy decisions and patient management in a large number of cancers across a variety of stages.
Summary:
• The data demonstrate that ctDNA can be a
reliable marker of the solid tumor in a large
number of tissue types in non‐metastatic cancers.
• These presurgical ctDNA can serve a surrogate
marker for patient prognosis.
swiftbiosci.com
Liquid Biopsy Publications with Swift Amplicons
56G panel
56G panel
56G panel
56G panel
56G panel
56G panel
swiftbiosci.com
Today’s Topic
Cancer Study
Genomic
Sequencing
RNA
Sequencing
Swift RNA library kit
Swift Rapid RNA library kit
After this training session:
• Able to know benefit of choosing each Swift DNA/ RNA library prep kit for cancer study
• Able to know benefit of Swift amplicon product
Amplicon
Panel
Hyb Capture
Swift DNA library prep kit+
Swift hyb capture panel / 3rd party panel
• Accel-NGS 2S kit
• Accel-NGS 1S kit
• 2S Turbo
• 2S Sonic
DNA
Methylation
WGS
Swift gene/cancer-
based panel
Somatic/germline
mutation detection
Fusion gene
Alternative splicing
RNA expression
Rare & novel transcripts
Disease-associate SNV
…
Hyb Capture WGBS
Swift Methyl-seq Kit+
Arbor Bio myBaits MethylCap
Swift Methyl-seq Kit
Hyb Capture RNA-seq
Swift RNA library kit or
Swift Rapid RNA library kit
+
Swift hyb capture panel / 3rd
party panel
swiftbiosci.com
THANKS!
We need your feedback!

More Related Content

What's hot

Analyzing Fusion Genes Using Next-Generation Sequencing
Analyzing Fusion Genes Using Next-Generation SequencingAnalyzing Fusion Genes Using Next-Generation Sequencing
Analyzing Fusion Genes Using Next-Generation Sequencing
QIAGEN
 
QIAseq Targeted DNA, RNA and Fusion Gene Panels
QIAseq Targeted DNA, RNA and Fusion Gene PanelsQIAseq Targeted DNA, RNA and Fusion Gene Panels
QIAseq Targeted DNA, RNA and Fusion Gene Panels
QIAGEN
 
Semi Automated Low-throughput Workflow for Microbial Analyses of Human Stool
Semi Automated Low-throughput Workflow for Microbial Analyses of Human StoolSemi Automated Low-throughput Workflow for Microbial Analyses of Human Stool
Semi Automated Low-throughput Workflow for Microbial Analyses of Human Stool
QIAGEN
 
Achieve Complete Coverage of the SARS-CoV-2 Genome
Achieve Complete Coverage of the SARS-CoV-2 GenomeAchieve Complete Coverage of the SARS-CoV-2 Genome
Achieve Complete Coverage of the SARS-CoV-2 Genome
Camille Cappello
 
Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...
Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...
Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...
QIAGEN
 
DNA Sequencing from Single Cell
DNA Sequencing from Single CellDNA Sequencing from Single Cell
DNA Sequencing from Single Cell
QIAGEN
 
Advanced NGS Library Prep for Challenging Samples
Advanced NGS Library Prep for Challenging SamplesAdvanced NGS Library Prep for Challenging Samples
Advanced NGS Library Prep for Challenging Samples
QIAGEN
 
RNA Sequencing from Single Cell
RNA Sequencing from Single CellRNA Sequencing from Single Cell
RNA Sequencing from Single Cell
QIAGEN
 
Next-generation genomics: an integrative approach
Next-generation genomics: an integrative approachNext-generation genomics: an integrative approach
Next-generation genomics: an integrative approach
Hong ChangBum
 
Whole Genome Amplification from Single Cell
Whole Genome Amplification from Single CellWhole Genome Amplification from Single Cell
Whole Genome Amplification from Single Cell
QIAGEN
 
Exploring new frontiers with next-generation sequencing
Exploring new frontiers with next-generation sequencingExploring new frontiers with next-generation sequencing
Exploring new frontiers with next-generation sequencing
QIAGEN
 
Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
Integrated DNA Technologies
 
The Importance of Quality Control Steps in Experiments
The Importance of Quality Control Steps in ExperimentsThe Importance of Quality Control Steps in Experiments
The Importance of Quality Control Steps in Experiments
QIAGEN
 
Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...
Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...
Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...
QIAGEN
 
Custom Enrichment Panels for Targeted Next Generation Sequencing
Custom Enrichment Panels for Targeted Next Generation SequencingCustom Enrichment Panels for Targeted Next Generation Sequencing
Custom Enrichment Panels for Targeted Next Generation Sequencing
Integrated DNA Technologies
 
New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...
New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...
New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...
QIAGEN
 
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
QIAGEN
 
Bioinformatics workshop Sept 2014
Bioinformatics workshop Sept 2014Bioinformatics workshop Sept 2014
Bioinformatics workshop Sept 2014
LutzFr
 
Accurate detection of low frequency genetic variants using novel, molecular t...
Accurate detection of low frequency genetic variants using novel, molecular t...Accurate detection of low frequency genetic variants using novel, molecular t...
Accurate detection of low frequency genetic variants using novel, molecular t...
Integrated DNA Technologies
 
miScript Single Cell Poster
miScript Single Cell PostermiScript Single Cell Poster
miScript Single Cell Poster
QIAGEN
 

What's hot (20)

Analyzing Fusion Genes Using Next-Generation Sequencing
Analyzing Fusion Genes Using Next-Generation SequencingAnalyzing Fusion Genes Using Next-Generation Sequencing
Analyzing Fusion Genes Using Next-Generation Sequencing
 
QIAseq Targeted DNA, RNA and Fusion Gene Panels
QIAseq Targeted DNA, RNA and Fusion Gene PanelsQIAseq Targeted DNA, RNA and Fusion Gene Panels
QIAseq Targeted DNA, RNA and Fusion Gene Panels
 
Semi Automated Low-throughput Workflow for Microbial Analyses of Human Stool
Semi Automated Low-throughput Workflow for Microbial Analyses of Human StoolSemi Automated Low-throughput Workflow for Microbial Analyses of Human Stool
Semi Automated Low-throughput Workflow for Microbial Analyses of Human Stool
 
Achieve Complete Coverage of the SARS-CoV-2 Genome
Achieve Complete Coverage of the SARS-CoV-2 GenomeAchieve Complete Coverage of the SARS-CoV-2 Genome
Achieve Complete Coverage of the SARS-CoV-2 Genome
 
Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...
Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...
Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...
 
DNA Sequencing from Single Cell
DNA Sequencing from Single CellDNA Sequencing from Single Cell
DNA Sequencing from Single Cell
 
Advanced NGS Library Prep for Challenging Samples
Advanced NGS Library Prep for Challenging SamplesAdvanced NGS Library Prep for Challenging Samples
Advanced NGS Library Prep for Challenging Samples
 
RNA Sequencing from Single Cell
RNA Sequencing from Single CellRNA Sequencing from Single Cell
RNA Sequencing from Single Cell
 
Next-generation genomics: an integrative approach
Next-generation genomics: an integrative approachNext-generation genomics: an integrative approach
Next-generation genomics: an integrative approach
 
Whole Genome Amplification from Single Cell
Whole Genome Amplification from Single CellWhole Genome Amplification from Single Cell
Whole Genome Amplification from Single Cell
 
Exploring new frontiers with next-generation sequencing
Exploring new frontiers with next-generation sequencingExploring new frontiers with next-generation sequencing
Exploring new frontiers with next-generation sequencing
 
Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
 
The Importance of Quality Control Steps in Experiments
The Importance of Quality Control Steps in ExperimentsThe Importance of Quality Control Steps in Experiments
The Importance of Quality Control Steps in Experiments
 
Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...
Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...
Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...
 
Custom Enrichment Panels for Targeted Next Generation Sequencing
Custom Enrichment Panels for Targeted Next Generation SequencingCustom Enrichment Panels for Targeted Next Generation Sequencing
Custom Enrichment Panels for Targeted Next Generation Sequencing
 
New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...
New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...
New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...
 
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
 
Bioinformatics workshop Sept 2014
Bioinformatics workshop Sept 2014Bioinformatics workshop Sept 2014
Bioinformatics workshop Sept 2014
 
Accurate detection of low frequency genetic variants using novel, molecular t...
Accurate detection of low frequency genetic variants using novel, molecular t...Accurate detection of low frequency genetic variants using novel, molecular t...
Accurate detection of low frequency genetic variants using novel, molecular t...
 
miScript Single Cell Poster
miScript Single Cell PostermiScript Single Cell Poster
miScript Single Cell Poster
 

Similar to Apac distributor training series 3 swift product for cancer study

2012 10-24 - ngs webinar
2012 10-24 - ngs webinar2012 10-24 - ngs webinar
2012 10-24 - ngs webinar
Elsa von Licy
 
Ngs webinar 2013
Ngs webinar 2013Ngs webinar 2013
Ngs webinar 2013
Elsa von Licy
 
Expanding Your Research Capabilities Using Targeted NGS
Expanding Your Research Capabilities Using Targeted NGSExpanding Your Research Capabilities Using Targeted NGS
Expanding Your Research Capabilities Using Targeted NGS
Integrated DNA Technologies
 
Overview of the commonly used sequencing platforms, bioinformatic search tool...
Overview of the commonly used sequencing platforms, bioinformatic search tool...Overview of the commonly used sequencing platforms, bioinformatic search tool...
Overview of the commonly used sequencing platforms, bioinformatic search tool...
OECD Environment
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
Golden Helix
 
2013 02-14 - ngs webinar - sellappan
2013 02-14 - ngs webinar - sellappan2013 02-14 - ngs webinar - sellappan
2013 02-14 - ngs webinar - sellappan
Elsa von Licy
 
NGS Applications I (UEB-UAT Bioinformatics Course - Session 2.1.2 - VHIR, Bar...
NGS Applications I (UEB-UAT Bioinformatics Course - Session 2.1.2 - VHIR, Bar...NGS Applications I (UEB-UAT Bioinformatics Course - Session 2.1.2 - VHIR, Bar...
NGS Applications I (UEB-UAT Bioinformatics Course - Session 2.1.2 - VHIR, Bar...
VHIR Vall d’Hebron Institut de Recerca
 
Genome in a Bottle - Towards new benchmarks for the “dark matter” of the huma...
Genome in a Bottle - Towards new benchmarks for the “dark matter” of the huma...Genome in a Bottle - Towards new benchmarks for the “dark matter” of the huma...
Genome in a Bottle - Towards new benchmarks for the “dark matter” of the huma...
GenomeInABottle
 
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
QIAGEN
 
Peter Nagy, Columbia Agilent Symposium, Jan, 27 2012
Peter Nagy, Columbia Agilent Symposium, Jan, 27 2012Peter Nagy, Columbia Agilent Symposium, Jan, 27 2012
Peter Nagy, Columbia Agilent Symposium, Jan, 27 2012
sequencing_columbia
 
RNA capture sequencing enabled liquid biopsy screening
RNA capture sequencing enabled liquid biopsy screeningRNA capture sequencing enabled liquid biopsy screening
RNA capture sequencing enabled liquid biopsy screening
Biogazelle
 
Cignal lenti webinar
Cignal lenti webinarCignal lenti webinar
Cignal lenti webinar
Elsa von Licy
 
Targeted Single Cell Sequencing for Accurate Mutation Detection in Heterogene...
Targeted Single Cell Sequencing for Accurate Mutation Detection in Heterogene...Targeted Single Cell Sequencing for Accurate Mutation Detection in Heterogene...
Targeted Single Cell Sequencing for Accurate Mutation Detection in Heterogene...
QIAGEN
 
Oncogenomics july 2012
Oncogenomics july 2012Oncogenomics july 2012
Oncogenomics july 2012
Elsa von Licy
 
A targeted subgenomic approach for phylogenomics based on microfluidic pcr an...
A targeted subgenomic approach for phylogenomics based on microfluidic pcr an...A targeted subgenomic approach for phylogenomics based on microfluidic pcr an...
A targeted subgenomic approach for phylogenomics based on microfluidic pcr an...
SimonUribeConvers
 
Genome in a bottle for amp GeT-RM 181030
Genome in a bottle for amp GeT-RM 181030Genome in a bottle for amp GeT-RM 181030
Genome in a bottle for amp GeT-RM 181030
GenomeInABottle
 
Next Generation Diagnostics: Potential Clinical Applications of Illumina’sTec...
Next Generation Diagnostics: Potential Clinical Applications of Illumina’sTec...Next Generation Diagnostics: Potential Clinical Applications of Illumina’sTec...
Next Generation Diagnostics: Potential Clinical Applications of Illumina’sTec...
Ilya Klabukov
 
One-Stop Antibody Drug Discovery Services from GenScript ProBio
One-Stop Antibody Drug Discovery Services from GenScript ProBioOne-Stop Antibody Drug Discovery Services from GenScript ProBio
One-Stop Antibody Drug Discovery Services from GenScript ProBio
GenScript ProBio
 
Cignal webina
Cignal webinaCignal webina
Cignal webina
Elsa von Licy
 
xGen® Lockdown® Probes
xGen® Lockdown® ProbesxGen® Lockdown® Probes
xGen® Lockdown® Probes
Integrated DNA Technologies
 

Similar to Apac distributor training series 3 swift product for cancer study (20)

2012 10-24 - ngs webinar
2012 10-24 - ngs webinar2012 10-24 - ngs webinar
2012 10-24 - ngs webinar
 
Ngs webinar 2013
Ngs webinar 2013Ngs webinar 2013
Ngs webinar 2013
 
Expanding Your Research Capabilities Using Targeted NGS
Expanding Your Research Capabilities Using Targeted NGSExpanding Your Research Capabilities Using Targeted NGS
Expanding Your Research Capabilities Using Targeted NGS
 
Overview of the commonly used sequencing platforms, bioinformatic search tool...
Overview of the commonly used sequencing platforms, bioinformatic search tool...Overview of the commonly used sequencing platforms, bioinformatic search tool...
Overview of the commonly used sequencing platforms, bioinformatic search tool...
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
2013 02-14 - ngs webinar - sellappan
2013 02-14 - ngs webinar - sellappan2013 02-14 - ngs webinar - sellappan
2013 02-14 - ngs webinar - sellappan
 
NGS Applications I (UEB-UAT Bioinformatics Course - Session 2.1.2 - VHIR, Bar...
NGS Applications I (UEB-UAT Bioinformatics Course - Session 2.1.2 - VHIR, Bar...NGS Applications I (UEB-UAT Bioinformatics Course - Session 2.1.2 - VHIR, Bar...
NGS Applications I (UEB-UAT Bioinformatics Course - Session 2.1.2 - VHIR, Bar...
 
Genome in a Bottle - Towards new benchmarks for the “dark matter” of the huma...
Genome in a Bottle - Towards new benchmarks for the “dark matter” of the huma...Genome in a Bottle - Towards new benchmarks for the “dark matter” of the huma...
Genome in a Bottle - Towards new benchmarks for the “dark matter” of the huma...
 
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
 
Peter Nagy, Columbia Agilent Symposium, Jan, 27 2012
Peter Nagy, Columbia Agilent Symposium, Jan, 27 2012Peter Nagy, Columbia Agilent Symposium, Jan, 27 2012
Peter Nagy, Columbia Agilent Symposium, Jan, 27 2012
 
RNA capture sequencing enabled liquid biopsy screening
RNA capture sequencing enabled liquid biopsy screeningRNA capture sequencing enabled liquid biopsy screening
RNA capture sequencing enabled liquid biopsy screening
 
Cignal lenti webinar
Cignal lenti webinarCignal lenti webinar
Cignal lenti webinar
 
Targeted Single Cell Sequencing for Accurate Mutation Detection in Heterogene...
Targeted Single Cell Sequencing for Accurate Mutation Detection in Heterogene...Targeted Single Cell Sequencing for Accurate Mutation Detection in Heterogene...
Targeted Single Cell Sequencing for Accurate Mutation Detection in Heterogene...
 
Oncogenomics july 2012
Oncogenomics july 2012Oncogenomics july 2012
Oncogenomics july 2012
 
A targeted subgenomic approach for phylogenomics based on microfluidic pcr an...
A targeted subgenomic approach for phylogenomics based on microfluidic pcr an...A targeted subgenomic approach for phylogenomics based on microfluidic pcr an...
A targeted subgenomic approach for phylogenomics based on microfluidic pcr an...
 
Genome in a bottle for amp GeT-RM 181030
Genome in a bottle for amp GeT-RM 181030Genome in a bottle for amp GeT-RM 181030
Genome in a bottle for amp GeT-RM 181030
 
Next Generation Diagnostics: Potential Clinical Applications of Illumina’sTec...
Next Generation Diagnostics: Potential Clinical Applications of Illumina’sTec...Next Generation Diagnostics: Potential Clinical Applications of Illumina’sTec...
Next Generation Diagnostics: Potential Clinical Applications of Illumina’sTec...
 
One-Stop Antibody Drug Discovery Services from GenScript ProBio
One-Stop Antibody Drug Discovery Services from GenScript ProBioOne-Stop Antibody Drug Discovery Services from GenScript ProBio
One-Stop Antibody Drug Discovery Services from GenScript ProBio
 
Cignal webina
Cignal webinaCignal webina
Cignal webina
 
xGen® Lockdown® Probes
xGen® Lockdown® ProbesxGen® Lockdown® Probes
xGen® Lockdown® Probes
 

Recently uploaded

Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
Gokuldas Hospital
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
Traumasoft LLC
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 

Recently uploaded (20)

Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 

Apac distributor training series 3 swift product for cancer study

  • 1. swiftbiosci.com APAC Distributor Training Series: Swift Product for Cancer Study Jan 2021 Mengmeng Lin (mlin@swiftbio.com)
  • 2. swiftbiosci.com Swift Library Prep Overview: IP families Adaptase 2S/Amplicon Normalase Accel-NGS Methyl-Seq For quant-free library pooling Accel-Amplicon or SNAP Amplicon (Single-tube multiplex PCR) Swift 2S Turbo Accel-NGS 2S (PCR-free, Plus, Hyb) Accel-NGS 1S Accel-NGS For Ion Torrent Adaptase Module (single cell methyl) Accel-NGS XL for PacBio Swift RNA Swift Rapid RNA Done: 7th Dec Swift Product for Metagenomics Study 21st Dec Swift Product for Virus Study More Distributor Training: Feb 2021 Swift Product for Very Specific Application Not covered product Swift 2S Sonic
  • 3. swiftbiosci.com Today’s Topic Cancer Study Genomic Sequencing RNA Sequencing Swift RNA library kit Swift Rapid RNA library kit After this training session: • Able to know benefit of choosing each Swift DNA/ RNA library prep kit for cancer study • Able to know why choose amplicon workflow and why Swift amplicon product Amplicon Panel Hyb Capture Swift DNA library prep kit+ Swift hyb capture panel / 3rd party panel • Accel-NGS 2S kit • Accel-NGS 1S kit • 2S Turbo • 2S Sonic DNA Methylation WGS Swift gene/cancer- based panel Somatic/germline mutation detection Fusion gene Alternative splicing RNA expression Rare & novel transcripts Disease-associate SNV … Hyb Capture WGBS Swift Methyl-seq Kit+ Arbor Bio myBaits MethylCap Swift Methyl-seq Kit Hyb Capture RNA-seq Swift RNA library kit or Swift Rapid RNA library kit + Swift hyb capture panel / 3rd party panel
  • 4. swiftbiosci.com Type of Mutation in Cancer (1) Inherited (blood spot, whole blood, buccal swab, agricultural) An inherited gene mutation is present in the egg or sperm that formed the child. Germline mutation (because the cells that develop into eggs and sperm are called germ cells) or hereditary. Inherited mutations are thought to be a direct cause of only a small fraction of cancers. Germline calling where VAF = 50% or 100% (2) Acquired (Fresh frozen tissue, FFPE, cfDNA/ctDNA) An acquired mutation is not present in the zygote, but is acquired some time later in life. Somatic mutation Type: - Substitutions of one base by another - Insertions or deletions of small or large segment of DNA - Rearrangement (DNA has been broken and then rejoined to a DNA segment from elsewhere in the genome) - Copy number increase (increases from the two copies present in the normal diploid genome, also know as gene amplification) - Copy number reductions https://www.cancer.org/cancer/cancer-causes/genetics/genes-and-cancer/gene-changes.html Landscape of somatic mutations present in a single cancer genome Nature. 2009 April 9; 458(7239)
  • 6. swiftbiosci.com Genetic Risk Early Detection Patient Stratification Disease Staging Treatment Options Outcomes Relapse Monitoring Birth Death Treatment Natural History of Disease Clinical Care Early screening for germline mutation NGS for Cancer Studies Somatic mutation or biomarker detection “Personalized Medicine” Molecular diagnostic Target therapy or drug resistance test
  • 7. swiftbiosci.com https://www.illumina.com/science/customer-stories/icommunity-customer-interviews-case-studies/patton-jennings-tan-yan-ngs-oncology.html Hyb workflow: Swift DNA or RNA library prep kit + Swift or 3rd party capture panel Swift Amplicon: Accel or SNAP version WGS: Swift DNA library prep kit
  • 8. swiftbiosci.com 2S Turbo 2S Sonic Differentiators: Enzymatic fragmentation, fast and easy prep, competitive price point, flexible adapter options Key Applications: WGS (complex and/or small genomes), Targeted (exome, panels), Genotyping by NGS, CNVs, Metagenomics Target Customer: Production scale laboratories, such as: large PI, core lab and service providers Sample Types: gDNA, high quality FFPE, RNA (1st strand cDNA) Input Range: 1-250 human or microbial (3rd party adapters), 50-250ng human or 1-250ng microbial (Swift adapter) Differentiators: Mechanical Shearing, fast and easy prep, competitive price point, flexible adapter options Key Applications: WGS (complex and/or small genomes), Targeted (exome, panels), Genotyping by NGS, CNVs, Metagenomics Target Customer: Production scale laboratories, such as: large PI, core lab and service providers Sample Types: gDNA, high quality FFPE, cfDNA Input Range: 1ng-1ug human or microbial 1S Plus Adaptase 2S (Plus, Hyb, PCR-Free) Differentiators: ssDNA or ss/dsDNA mix, nicked DNA, RNA (1st strand cDNA), viral genome, highly degraded/ancient DNA, short fragments >40 bp…WHEN 2S FALLS SHORT! Key Applications: WGS/ Hyb, ChIP-Seq, Metagenomics Target Segment: Infectious Disease, Agriculture, Archeology/Museum, Forensics, Biotechnology, Biopharma, Academic and Government Labs Sample Types: highly degraded FFPE, Ancient DNA, degraded cfDNA, Very Low Input ChIP samples Input Range: >10pg Differentiators: Mechanical Shearing, degraded or dilute samples such as FFPE and cfDNA Key Applications: WGS (complex and/or small genomes), Targeted (exome, panels), ChIP-Seq, low frequency variant detection, CNV Target Customer: Sample Types: gDNA, FFPE, cfDNA, RNA (1st strand cDNA) amplicons Input Range: >10 pg (w/ PCR) 10 ng (cfDNA PCR-Free) 100 ng (gDNA PCR-Free) Swift Product Selection and Positioning Guide
  • 9. swiftbiosci.com Turbo Turbo New!! Swift 2S Turbo DNA Library Kits for Illumina® platforms With Enzymatic Shearing Tissue or Blood Sample Type for Cancer Study
  • 10. swiftbiosci.com Custom adapter guide(IDT): https://sfvideo.blob.core.windows.net/sitefinity/docs/default-source/supplementary-product-info/idt-custom-ngs-adapters-product-sheet.pdf?sfvrsn=45d71f07_6 Minimal enzymatic incubation & purification steps Indexing PCR Time varies Optional PCR Terminal primers (included) to increase library yield Time varies Ligation 3’ and 5’ ligation of P7 and p5 full-length adapters(Your choice of adapter) truncated adapters Flexible ✔️1-250 human or microbial ✔️ PCR-free Flexible New! Swift 2S Turbo V2 DNA Library Kits will launch soon Choice of Kits: Standard & flexible Standard ✔️50-250 human or 1-250ng microbial ✘ PCR-free
  • 11. Targeted sequencing 2S Turbo DNA library kit
  • 12. swiftbiosci.com Swift 2S Turbo Library Kit was evaluated for enrichment using Swift Exome and Pan-Cancer Hyb Panels. Comprehensive target coverage and high complexity was observed with multiple sample types, input quantities, and platforms. Coverage uniformity and complexity was higher with low input Turbo libraries compared to competitors (see highlighted region of table). Turbo’s efficient library provide more data at low input ! *FFPE and HD200 sample integrity quantified by qPCR using the Swift ALU repeat assay provide with the Swift library prep kits, 0.34 ratio obtained for both samples. Benchmarking: Hyb Capture Better Coverage Uniformity with low input
  • 13. swiftbiosci.com *FFPE and HD200 sample inputs quantified via qPCR of smaller ALU 115 repeat. +Based on 247/115 ALU repeat fragment ratios Sample Integrity+ Input (ng)* %Duplicates Mean Bait Coverage %Covered ≥ 20X %Covered ≥ 50X %Covered ≥ 100X % Bases On-Target 0.24 25 6 176X 99.5 98.3 90.7 73.8 0.26 25 8 173X 99.6 98.5 94.6 74.9 0.34 24 4 163X 99.1 98.1 89.7 70.3 0.34 79 6 151X 99.4 98.5 90.2 69.6 Uniform Coverage for Somatic Mutation Detection Targeted Sequencing of FFPE using Swift Exome Panel (MiSeq Run) Sequencing metrics of FFPE samples match control samples (e.g. NA12878 % bases on target = 68-75%).
  • 14. swiftbiosci.com Swift Deceleration Module to control fragmentation reaction time for automation 15 uL 10 uL 3 uL 1.5 uL 5 uL Reagent DE into frag reaction Fragment Mode (bp) 1.5 uL 382 3 uL 434 5 uL 467 10 uL 600 15 uL 750 Automation Request • Slow fragmentation to 15 min for 350-400bp • Prepare reaction at room temp • Sample placed on cycler 10 min after adding fragmentation mix Actions • Tested various volumes of Reagent DE in fragmentation reaction • Ensured reproducible fragmentation, and no influence in Exome Capture Will be added to Turbo protocol ☺︎ large insert size (>350bp) (ie, metagenomics) ☺︎ Automation ☺︎ SOP ☺︎ Similar fragment time for various condition of degraded samples
  • 15. swiftbiosci.com Accel-NGS® 2S DNA Library Kits With Mechanical Shearing For balanced coverage of dsDNA, even at low input
  • 16. swiftbiosci.com Swift 2S: Superior Data Quality High adapter ligation efficiency  Unique 3’ end repair that efficiently converts all 3’-P into 3’-OH and at the same time prevents chimera formation  Unique 5’ end repair that replaces bases damaged by physical shearing  No A-tailing  No adapter titration for low inputs maintains high ligation efficiency  Very low adapter dimers  Introduces Molecular ID tags (MIDs) Best Data Quality  WGS and exome sequencing  Metagenomic sequencing (ultra-low inputs <1ng down to 10 pg)  ChIP-Seq (including ultra-low inputs down to 10 pg)  FFPE and cfDNA/ctDNA (>10 ng PCR-Free)  HiC-Seq (as low as 5000 cells)
  • 17. FFPE Sample Accel-NGS® 2S DNA Library Kits
  • 18. swiftbiosci.com 2S Hyb Performance with Fixed Samples of Various Fixation Times and Input Levels Fixation Time Course with the Pan-Cancer Panel Accel-NGS® 2S Hyb libraries were constructed with 100, 10, and 1 ng of DNA. DNA extracted from the same normal kidney sample which had either been fresh-frozen or fixed for 6, 24, or 48 hours before being paraffin- embedded. Amplified libraries were enriched with the IDT xGen® Pan-Cancer Panel. The xGen Pan-Cancer Panel is 0.9Mb and all samples were normalized to 0.6Mb reads. INPUT QUANTITY SAMPLE TYPE % ALIGNED % DUPLICATION MEAN BAIT COVERAGE % COVERED > 1X % COVERED > 20X % BASES ON TARGET 100 ng Frozen 96 1 42X 99 91 80 6 Hr. Fix 96 1 43X 99 93 81 24 Hr. Fix 97 1 44X 99 93 82 48 Hr. Fix 97 1 45X 99 88 82 10 ng Frozen 96 3 42X 99 90 80 6 Hr. Fix 96 5 41X 99 92 80 24 Hr. Fix 97 4 42X 99 93 81 48 Hr. Fix 97 8 42X 99 86 81 1 ng Frozen 95 18 33X 99 85 77 6 Hr. Fix 94 32 26X 99 77 74 24 Hr. Fix 95 31 27X 100 79 76 48 Hr. Fix 95 44 22X 99 53 73
  • 19. swiftbiosci.com Choice of Index- MID Enable accurate de-duplication from single read sequencing, and distinguishing PCR duplicates from fragmentation and strand duplicates. Posters 9 base N sequence 6 or 8 base
  • 20. swiftbiosci.com Choice of Index- MID Only 1x coverage was retained post- deduplication increase in data retention up to 6x coverage post deduplication.
  • 21. swiftbiosci.com MID Enable Ultra-Low Frequency Variant Detection cfDNA was extracted from blood of four individuals with unique genetic background and Coriell gDNA samples from different genetic backgrounds were obtained. To determine the effect of MIDs on low frequency variant calling, sample spike-ins were performed at 1% or 0.5% frequency into 10 ng cfDNA or 100 ng gDNA. Libraries were prepared with the Swift 2S Hyb kit with MIDs, enriched with the Swift Pan-Cancer Hyb Panel , and sequenced on an Illumina HiSeq ® to a minimum of 8000x coverage. A consensus sequence was generated for each MID family (BMFtools) and data were analyzed for homozygous SNPs present in the spike-in sample only. 6/6 known variants were present in all three 1% cfDNA samples and 27/27 known variants were present in both 1% and 0.5% gDNA samples depicting the power of MIDs for low frequency variant calling.
  • 22. swiftbiosci.com Patient- derived xenografts (PDX) CTC-derived xenografts (CDX) Cancer Discov; 6(3); 286–99. Cancer Research UK Manchester Institute WES + multiplex PCR panel, long term monitoring response of sequential targeted, immuno- and chemotherapy of one melanoma patient. 10-25 ng cfDNA WES) swift 2S Cancer Research UK Manchester Institute • 214 patients (364 samples) with stage II, III, IV melanoma • 13ng cfDNA (WES on Miseq) swift 2S ) • Application: Facilitate individualized treatment decisions for patients with advanced melanoma Publication for Clinical-based
  • 23. swiftbiosci.com Part A (100 patients,22 tumor type) Part B (450 patients) Workflow establishment & test its feasibility Workflow for ctDNA test: 4x 10mL Streck ↓ Manual purification: QIAmp Circulating Nucleic Acid Kit (Qiagen) Automation purification: :QIAsymphony (Qiagen) ↓ 0.5 to 25 ng ctDNA for Accel-NGS 2S DNA Library Kits ↓ SureSelectXT Reagent Kits (Agilent) 641-gene panel, 2.1Mb ↓ Illumina NextSeq 500, 2 × 150 bp TARGET (Tumor chARacterisation to Guide Experiment Target therapy) Aim: Use ctDNA to identify clinically actionable mutations in early phase clinical trail patients with a range of advanced-stage cancers. Publication for Clinical-based
  • 24. swiftbiosci.com Accel 2S Plus – Best Coverage and Superior Variant Detection in ccfDNA • Prostate cancer plasma sample • Prepared 10ng ccfDNA with Accel 2S Plus, along with 3 other library prep kits. • Sequenced on Illumina HiSeqX (2 x 150bp PE) • Analyzed CNV, SNV and Indels • Accel 2S Plus kit detected more variants and specific SNVs, INDELs and CNVs. • Accel 2S Plus provided the best coverage Mauger, F., et al. Comparison of commercially available whole-genome sequencing kits for variant detection..., Sci Rep 10, 6190 (2020) Publication for Methodology Comparison
  • 25. swiftbiosci.com Accel-NGS® 1S Plus DNA Library Kit For Difficult-to-Process Samples Including Damaged, Denatured, or ssDNA
  • 26. swiftbiosci.com Accel-NGS® 1S Plus Specifications • Broad input range from 10 pg to 250 ng • Adapt strands of DNA ≥ 40 bp long • Simple, 2-hour protocol • Offered for Ion Torrent™ and Illumina ® • No end polishing step Features • Capture previously unattainable sequences • Process more samples per day • Use platform of choice • Preserve input fragmentation patterns for precise mapping of DNA insert ends Benefits Ion Torrent is a trademark of Thermo Fisher Scientific. Illumina is a registered trademark of Illumina, Inc. Adaptase tail Truncated P7 adapter ssDNA
  • 27. swiftbiosci.com Cancer Research UK Cambridge Institute 200 patients (18 different cancer types) 65 plasma samples 90–150 bp 180–220 bp 250–320 bp High ctDNA: breast, ovarian, lung, melanoma, colorectal, and cholangiocarcinoma Low ctDNA: glioma, renal, pancreatic, and bladder cancers. Mutant ctDNA is generally more fragmented than non- mutant cfDNA (19 cancer patients) Mutant DNA in plasma of patients with advanced cancer is consistently shorter than predicted mono-, and di-nucleosomal DNA fragment lengths
  • 28. swiftbiosci.com 6.4倍富集 4倍富集 Longitudinal plasma samples of a colorectal cancer patient Detect tumor progression 60 and 87 days before by imaging or unselected t-MAD analysis. Improve the detection of response or disease progression 60 days 87 days
  • 29. swiftbiosci.com AUC = 0.97 (sens: 90% & spec:98%) AUC = 0.64 4.19X SNVs Conclusion:Size selection of shorter plasma DNA fragments enriches ctDNA and assists in the identification of a greater number of genomic alterations with both targeted and untargeted sequencing at minimal additional cost. Increased number of mutations detected in plasma (samples from 6 patients with HGSOC)
  • 30. swiftbiosci.com https://www.illumina.com/science/customer-stories/icommunity-customer-interviews-case-studies/patton-jennings-tan-yan-ngs-oncology.html Hyb workflow: Swift DNA or RNA library prep kit + Swift or 3rd party capture panel Swift Amplicon: Accel or SNAP version WGS: Swift DNA library prep kit
  • 32. swiftbiosci.com Feature Specification Benefit Input Quantity 10 ng – 1 g total RNA 100 pg – 100 ng mRNA Supports a Wide Range Consistent Library Output RNA Types Supported Poly(A)-enriched mRNA Ribodepleted RNA Total RNA Supports Most RNA Applications Technology Adaptase® tailing and ligation of 1st strand cDNA No 2nd Strand cDNA No Adapter Titration Lowest Dimers & Duplicates Maintains Strandedness, High Mapping & Detection Time 4.5 hours Save 1 hour vs. NEBNext® Half the time of TruSeq® Kit Reaction Sizes 24 • 96 Evaluation and Adoption Indexing Options Single • Combinatorial Dual Unique Dual • Normalase Flexible to Sequencers, Workflows and Applications Multiplexing Capability Up to 768 libraries Save Sequencing Costs Automation Compatible with Liquid Handlers Custom Packaging Available Adopt at Scale Fast Lowest Inputs Low Cost Feature Specification Benefit Input Quantity 100 ng – 1 g total RNA 5 ng – 100 ng mRNA Supports a Wide Range RNA Types Supported Poly(A)-enriched mRNA Ribodepleted RNA Total RNA Supports Most RNA Applications Technology Adaptase® tailing and ligation of 1st strand cDNA High Strandedness No 2nd Strand cDNA No Adapter Titration Time 3.5 hours Fastest on Market Kit Reaction Sizes 24 • 96 Evaluation and Adoption Indexing Options Single • Combinatorial Dual Unique Dual • Normalase Flexible to Sequencers, Workflows and Applications Multiplexing Capability Up to 768 libraries Save Sequencing Costs Automation Compatible with Liquid Handlers Custom Packaging Available Adopt at Scale Fastest Lowest Cost Swift Rapid RNA Library Kit Accelerate Your RNA-Seq Discovery Swift RNA Library Kit Deepen Your RNA-Seq Discovery
  • 33. swiftbiosci.com Why not Poly(A)?  10ng RNA for Swift RNA Library Kit  100ng RNA for Swift Rapid RNA Library Kit  100pg RNA for Swift RNA Library Kit  5ng RNA for Swift Rapid RNA Library Kit
  • 34. swiftbiosci.com Ribodepletion VS. Capture Sample Library yield (nM) STAR mapping rate (%) Genes detected Exonic rate (%) rRNA rate (%) ERCC (R2 ) UHR RNA 44.2 86.2 17,132 46.0 3.4 0.94 33.6 87.5 17,180 46.2 3.2 0.92 FFPE Sample 1 14.0 83.6 15,095 22.0 6.7 0.91 19.8 85.7 15,112 21.2 6.0 0.92 FFPE Sample 2 24.9 84.2 15,274 24.6 4.8 0.92 23.9 85.5 15,325 25.7 4.5 0.94 UHR FFPE Sample 1 FFPE Sample 2 UHR Ribo- depleted UHR FFPE Sample 1 FFPE Sample 2 Sample Library yield (ng/uL) STAR mapping rate (%) Genes detected Exonic rate (%) rRNA rate (%) Selected bases (%) UHR RNA 82 89.6 17,758 91.2 1.3 96.7 FFPE Sample 1 93 88.8 17,009 89.2 0.9 96.5 FFPE Sample 2 73 87.9 17,024 88.1 1.0 95.8 Sample Library yield (ng/uL) STAR mapping rate (%) Genes detected Exonic rate (%) rRNA rate (%) Selected bases (%) FFPE Sample 3 23.0 89.4 16,089 87.4 1.5 95.1 FFPE Sample 4 54.0 88.0 16,065 88.7 1.3 95.6 FFPE Sample 5 33.4 87.5 15,653 87.6 1.3 94.6 FFPE Sample 6 56.0 87.6 16,246 88.4 1.2 95.4 DV200 = 60 DV200 = 61 DV200 = 54 DV200 = 54 Ribodepletion (100ng of total RNA input) Capture (100ng of total RNA input) Capture (10ng of total RNA input) https://swiftbiosci.com/wp-content/uploads/2020/01/APP-004-THE-SWIFT-RNA-LIBRARY-KIT-OPTIMIZES-RNA-SEQ-DATA-QUALITY-AND-COSTS-FOR-FFPE- SAMPLES-Rev-1.pdf
  • 35. swiftbiosci.com Capture Workflow for Lower Inputs Swift RNA on FFPE samples 100 pg total RNA 20 PCR cycles Yields > 20 nM 1:10 dilution loaded on Bioanalyzer HS DNA chip 10 ng total RNA 16 PCR cycles Yields > 100 nM HER2- Sample 1 DV200 = 54 HER2+ Sample 4 DV200 = 61 HER2- Sample 3 DV200 = 54 Confidential HER2- Sample 1 DV200 = 54 HER2+ Sample 4 DV200 = 61 HER2- Sample 3 DV200 = 54
  • 36. swiftbiosci.com HER2- Sample 4 DV200 = 73 327 bp 93 ng/uL HER2+ Sample 6 DV200 = 48 296 bp 73 ng/uL 100 ng FFPE RNA input directly into Swift library prep kits 1:10 dilution loaded on Bioanalyzer HS DNA chip Library details: • 100 ng total RNA • 2 min @ 94 C adjusted fragmentation time • Relaxed 1.8X SPRIs throughout • 12 PCR cycles HER2- Sample 4 DV200 = 73 318 bp 58 ng/uL HER2+ Sample 6 DV200 = 48 282 bp 66 ng/uL Capture Workflow for Both Swift Kits Swift RNA& Rapid RNA Library Kits on FFPE RNA (pre-hyb) Swift RNA Swift Rapid RNA
  • 37. swiftbiosci.com Today’s Topic Cancer Study Genomic Sequencing RNA Sequencing Swift RNA library kit Swift Rapid RNA library kit After this training session: • Able to know benefit of choosing each Swift DNA/ RNA library prep kit for cancer study • Able to know why choose amplicon workflow and why Swift amplicon product Amplicon Panel Hyb Capture Swift DNA library prep kit+ Swift hyb capture panel / 3rd party panel • Accel-NGS 2S kit • Accel-NGS 1S kit • 2S Turbo • 2S Sonic DNA Methylation WGS Swift gene/cancer- based panel Somatic/germline mutation detection Fusion gene Alternative splicing RNA expression Rare & novel transcripts Disease-associate SNV … Hyb Capture WGBS Swift Methyl-seq Kit+ Arbor Bio myBaits MethylCap Swift Methyl-seq Kit Hyb Capture RNA-seq Swift RNA library kit or Swift Rapid RNA library kit + Swift hyb capture panel / 3rd party panel
  • 38. swiftbiosci.com Accel-NGS® Methyl-Seq DNA Library Kits Library Preparation for Bisulfite-Converted DNA
  • 39. swiftbiosci.com Adaptase-based (1S, Methyl, Module, RNA) U U U U U U U U U Powered by Swift’s Adaptase® Technology •Single-stranded tailing and ligation •Template-independent reaction •>90% efficiency •US Patent 9,896,709 •Underlying technology of Swift Methyl-Seq and Single Cell Methyl (Adaptase Module) and 1S Plus Library Kit Benefits to Methyl-seq • >40bp retention • Lower input requirement • Able to use ss&dsDNA as library prep template
  • 40. swiftbiosci.com PreBS PostBS 2% amplifiable fraction - High input - Low yield - High dup% - Low diversity% PBAT - Uneven coverage - High dup% - Low diversity Target towards CpGs
  • 41. swiftbiosci.com 4841 participants CCGA Study PATHFINDER Study STRIVE Study SUMMIT Study Current Status Follow-up (>5 year) Enroll Follow-up (5 year) Enrolling Actual/Expected Enrollment 15254 participants 6,200 participants 99481 participants (women) 50,000 participants Sample Type Blood and tumor tissue A single blood draw Blood Blood Time Perspective/ Purpose Prospective Screening Prospective Prospective Actual Study Start Date August 2016 December 2019 February 2017 April 2019 Estimated Completion March 2024 June 2021 May 2025 August 2030 https://grail.com/clinical-studies/ On-going Clinical Trials
  • 42. swiftbiosci.com https://doi.org/10.1016/j.annonc.2020.02.011 4841 participants Annals of Oncology >50 Cancer type Adrenal (cortical carcinoma and neuroendocrine), ampulla of Vater, anus, appendix, bone, brain and spinal cord, breast, cervical lymph nodes and unknown primary tumors of the head and neck, cervix uteri, colon and rectum, corpus uteri… STRIVE study Training set + 1587 Validation + 615 6689 total WGBS vs. WGS vs. target sequencing Population-level screening
  • 43. swiftbiosci.com Step 5 Targeted Enrichment Sequenced fragments are associated back to regions of interest Step 6 Median depth: 113 million median unique on-target depth: 139X 150bp PE sequencing, NovaSeq Step 1 CCGA :8 tubes of 10mL whole blood STRIVE: 4 tubes of 10mL whole blood (Streck) Centrifuge:<5days,median <2 days Step 4 Swift Methyl-seq kit for library preparation WGBS; 30X depth (n=3,508) Twist panel (17.2Mb) 1,116,720 CpG (~10 regions) 7.5Mb hypomethylated sites 7.4Mb hypermethylated sites 2.3Mb target both Step 3 Bisulfite conversion: EZ-96 DNA Methylation Kit (Zymo) ≥0.99 conversation rate Step 2 10mL plasma, 75ng cfDNA Manual: QIAamp Circulating Nucleic Acid kit Automation: MagMax kit (ThermoFisher)
  • 44. Enroll population: progressing advanced cancers(2011- 2016) Sample collection: 1-4mLplasma (ETDA tube Purification: QIAamp Circulating Nucleic Acid kit (4.5-30ng, avg 21.1ng) BS: EZ DNA Methylation-Lightning Kit (Zymo Research) Library Prep: Accel-NGS Methyl- Seq DNA Library Kit (Swift Biosciences) Hyb Capture: llumina TruSight Rapid Capture Kit Sequencing: Illumina HiSeq 2500 (2x100 cycle) ~10,000x mean target coverage Targeted Methylation Sequencing of Plasma Cell-free DNA for Cancer Detection and Classification MD Anderson Cancer Center, Phase I Clinical Trials 9223 CpG sites, 32 cancer type ( hypermethylated in tumors ) Liu. L, F.Janku, et. Al, 2018. Annals of Oncology 37 samples from late phase of CRC Cutoff 7.52 Sens: 94.4% Spe: 100% Performance Evaluation Publication for Clinical-based
  • 45. (A) Patients on therapy had lower methylation rates (B) Patients with lower methylation rates (blue) had longer survival rates (C) Patients with lower methylation rates had longer time to treatment failure (D) Positive correlation between methylation score and best RECIS (response) score Liu. L, F.Janku, et. Al, 2018. Annals of Oncology 68 patients off therapy (83.8% sens) 14 patients on therapy (50% sens) OS Off-therapy TTF 55 patients 10.4 months 4.4 months 1.6 months 2.8 months Clinical validation(78 patients with advanced colorectal cancer, non-small-cell lung cancer (NSCLC), breast cancer or melanoma Targeted Methylation Sequencing of Plasma Cell-free DNA for Cancer Detection and Classification MD Anderson Cancer Center, Phase I Clinical Trials Publication for Clinical-based
  • 46. swiftbiosci.com Publication for Research-based A large integrated study of WGS, WGBS and whole-transcriptome, first study to look at comprehensive methylation landscape in metastatic prostate cancer. Observed that 22% of tumors exhibited a novel epigenomic subtype associated with hypermethylation and somatic mutations in these four driver genes: TET2, DNMT3B, and BRAF.
  • 47. swiftbiosci.com Publication for Research-based Wu et al., 2020, The Journal of Clinical Investigation Characterize the plasma methylome in mCRPC and identify prostate cancer–specific methylation signatures. University College London Cancer Institute
  • 48. swiftbiosci.com Publication for Methodology Development Uses the methylation profiles of adjacent CpG sites on an individual read to accurately identify the tumor cfDNA fraction in plasma. CancerDetector-generated tumor burden percentages correlated well with tumor size (0.87) and can thus be used to monitor disease progression and treatment. This publication describes CancerLocator, a method that simultaneously infers the proportion and tissue of origin of ctDNA in a blood sample using WGBS. CancerLocator performance was evaluated on both simulated data and real data, and compared to that of 2 established multi-class classification methods
  • 49. swiftbiosci.com Publication for Methodology Comparison NanyangTechnological University, Singapore;UCL The Accel-NGS Methyl-Seq kit had the best GC coverage across both genomes Accel-NGS Methyl-Seq TruSeq Methyl-Seq NEBNext Ultra SPLAT (home brew) Accel-NGS Methyl-Seq TruSeq Methyl-Seq QIAseq Methyl Library kit
  • 50. swiftbiosci.com Swift Solution for Target Methyl Study Swift Methyl-Seq + Arbor Bio myBaits MethylCap + https://swiftbiosci.com/wp-content/uploads/2020/10/AppNote_Arbor-Swift_MethylSeq_2020-3.pdf Webinar: https://www.youtube.com/watch?v=iZydUU-DZgI
  • 51. swiftbiosci.com https://www.illumina.com/science/customer-stories/icommunity-customer-interviews-case-studies/patton-jennings-tan-yan-ngs-oncology.html Hyb workflow: Swift DNA or RNA library prep kit + Swift or 3rd party capture panel Swift Amplicon: Accel or SNAP version WGS: Swift DNA library prep kit
  • 53. swiftbiosci.com • Consists of individually synthesized and quality controlled probes that have been validated to provide the highest level of performance • ~9-hour workflow • 500 ng per library, up to 12-plex • 150-350 bp fragment size • Customizable Swift Hybridization Capture Kits Accel-Amplicon™ Panels • Accel-Amplicon and SNAP Panels combine the easiest, fastest workflow with flexible content to accelerate your variant discovery and screening. Simply leverage our pre-designed, validated core content and add your own targets. • ~2-hour (Accel)/ ~3-hour (SNAP) workflow • 10 ng input sample • Average amplicon size ~130-140bp • Customizable Panel size Gene Panels (<50genes) Gene Panels (>50genes) DAR (Disease associate regions) Exome 20-30%Probes 70-80%Amplicon 50%Probes 50%Amplicon 70-80%Probes 20-30%Amplicon 80-90%Probes 10-20%Amplicons
  • 54. swiftbiosci.com Swift Amplicon NGS Panels Format • Core + customizable gene content • Single-tube, highly multiplexed assay • DNA to library in 2 hours for Accel-amplicon 3 hours for SNAP panel workflow • 10 ng input of cfDNA or FFPE DNA • Illumina®, Ion Torrent™ for Accel-amplicon Only Illumina® for SNAP Panels Performance • Limit of detection of 1% VAF • On-target > 90% • Coverage uniformity > 90% • Compatible with cfDNA and FFPE • Supports limited amounts of DNA • Cost-effective Accel-amplicon SNAP amplicon
  • 55. swiftbiosci.com • Low uniformity and lack of coverage • Multiple primer pools increase the input requirement • You need large contiguous stretches of DNA in order to make library • Inflexibility to add primers to increase the size of the panel • Low library complexity • Inability to cover entire coding regions Traditional two-primer strategy
  • 56. swiftbiosci.com Competitors of Two-Primes Panel https://www.youtube.com/watch?v=D3Dv7QHpLcs
  • 57. swiftbiosci.com • OVERLAPPING AMPLICONS IN A SINGLE REACTION • Low total input • Few reagents, less time • Fast workflow • ~2hrs or 3hrs • Accel-Amplicon™ or SNAP Amplicon panels may be used to interrogate the following types of variants in samples: - SNV - Insertions and deletions - CNV Why are Swift Amplicon Products Special? Multiplex PCR with overlapping target specific-primers
  • 58. Swift Panel Design base on OncoKB and market research Included OncoKB Introduction https://www.youtube.com/watch?v=XqoKrrm2Boc&feature=youtu.be Swift used: FDA-recognized biomarkers Standard of care biomarkers
  • 59. Available Panels 56G and 57G Pan-Cancer Profiling EGFR Pathway (KRAS/NRAS/BRAF) BRCA1 and BRCA2 BRCA1, BRCA2 and PALB2 TP53 (all exons) CFTR (all exons, UTRs, some introns) Sample_ID Colorectal Cancer Lynch Syndrome Myeloid Disease Lung Cancer Gene-Based Disease-Based
  • 60. swiftbiosci.com • ERASE-Seq (Elimination of Recurrent Artifacts and Stochastic Errors) functions by quantitatively modeling the background error profile of normal controls that have gone through the library prep and sequencing process in order to establish the inherent noise distribution for each possible variant • ERASE-Seq delivers superior detection sensitivity to 0.05% allele frequency (AF), with a false positive rate 10-100X lower than leading molecular barcode. Benefits: • Superior sensitivity and 10-100X fewer false positives than molecular barcodes (UMIs) • Excels in the 0.05%-0.5% AF range where molecular barcodes struggle • Any targeted panel can be adapted easily to ERASE-Seq with software validation- and no barcodes needed • Provides similar detection performance to digital PCR, but can test for thousands of variants per test • Validated in numerous sequencing labs globally
  • 61. swiftbiosci.com Swift Amplicon HS Panels Confident Detection of Low Frequency Variants in Liquid Biopsy Sequencing
  • 62. swiftbiosci.com Swift Amplicon HS – Features, Benefits, Pricing Features and Benefits • Sensitive and Specific Robustly detect SNVs and indels down to 0.2% • Compatible with cfDNA Amplifies from 10-20 ng of cfDNA • Fast workflow, high quality data From DNA to Illumina® libraries within 3 hours • Paired Data Analysis Tools Cloud-based via Genialis or open-source Ordering Information Swift Amplicon HS EGFR Panel, Cat. No. HS-51024, 24 rxns A focused cfDNA-compatible panel covering clinically-relevant oncology hotspots including EGFR T790, KRAS G12/G13,NRAS Q61 and BRAF V600
  • 63. swiftbiosci.com Turbo flexible + IDT Probes 10-100 amplicons/tube 15-1,500 amplicons/tube
  • 64. Using a custom panel targeting 30 hotspot amplicons in these four genes, NGS was performed on cell-free DNA extracted from plasma at the time of hysterectomy and the matching tumor DNA from 48 patients with endometrioid endometrial carcinomas. These results demonstrate that mutations in genes relevant to endometrial cancer can be identified in the peripheral blood of patients at the time of surgery
  • 65.
  • 66. swiftbiosci.com Conclusion: ctDNA could be a powerful tool for therapy decisions and patient management in a large number of cancers across a variety of stages. Summary: • The data demonstrate that ctDNA can be a reliable marker of the solid tumor in a large number of tissue types in non‐metastatic cancers. • These presurgical ctDNA can serve a surrogate marker for patient prognosis.
  • 67. swiftbiosci.com Liquid Biopsy Publications with Swift Amplicons 56G panel 56G panel 56G panel 56G panel 56G panel 56G panel
  • 68. swiftbiosci.com Today’s Topic Cancer Study Genomic Sequencing RNA Sequencing Swift RNA library kit Swift Rapid RNA library kit After this training session: • Able to know benefit of choosing each Swift DNA/ RNA library prep kit for cancer study • Able to know benefit of Swift amplicon product Amplicon Panel Hyb Capture Swift DNA library prep kit+ Swift hyb capture panel / 3rd party panel • Accel-NGS 2S kit • Accel-NGS 1S kit • 2S Turbo • 2S Sonic DNA Methylation WGS Swift gene/cancer- based panel Somatic/germline mutation detection Fusion gene Alternative splicing RNA expression Rare & novel transcripts Disease-associate SNV … Hyb Capture WGBS Swift Methyl-seq Kit+ Arbor Bio myBaits MethylCap Swift Methyl-seq Kit Hyb Capture RNA-seq Swift RNA library kit or Swift Rapid RNA library kit + Swift hyb capture panel / 3rd party panel

Editor's Notes

  1. In cancer research each cancer sample presents the researcher with an altered genome that contains a unique and unpredictable number of point mutations, indels, translocations, fusions, and other aberrations.
  2. Turbo is the only swift DNA library prep kit using enzymatic fragment method, because the workflow is simple & fast with robust performance hence it’s suitable for large scale lab as routine use. The easiest way to differentiate turbo from 2S & 1S is to check with input range.. 1S- Aaptase, 2S special workflow, allow down to 10pg Because tubo use enzyme to fragment DNA samples & cannot separate from master mix, as a reulst, tubo cannot support already fragmentated DNA samples such as short amplicon or cfDNA. DNA library pre kit for everyday samples & routine use. 1. Flexible & fast robust workflow & adapter choice 2. Wide input range
  3. Two workflow for customer depends on their choice of index, if customer want to choose index directly from swift, that’s the left workflow. Or they want to choose their own full-length adapter, it’s the right workflow. The upfront workflow is the same. We have validated up too 768-plex CD or 96-plex UDI Otherwise they can go to other suppliers of adapter such as IDT, KAPA as long as it’s TA ligation & full-length adapter We also compatible with various type of capture probes brands. Not compatible with cfDNA Ligation: ligate truncated ds adapter & finishing library construction by PCR
  4. Automation, hand multiple plate on one time, don’t have on deck chillers
  5. Physical frag method create damaged DNA, no enzyme in traditional polishing mix can tim a damaged 5’ base, cause a substantial fraction of DNA fag. do not get converted into NGS molecules. Damaged 5’ remain ligation incompatible to NGS adapters Sequential ligation prevents adapter dimer formation and allows optimized ligation to each strand. Equivalent efficiency at all inputs, no adapter titration needed. During Ligation I, the P7 adapter is attached to the repaired 3’ termini. During Ligation II, the P5 adapter is attached to the repaired 5’ termini.
  6. DNA from FFPE samples is susceptible to substantial damage resulting from the fixation process, leading to cross-linking and fragmentation Oxidation damage of DNA in FFPE samples also accumulates over time Accel-NGS kit chemistry can handle both damaged and short DNA fragments Ideally suited for clinical samples, such as FFPE or plasma
  7. Whole exome sequencing (WES) and targeted sequencing of circulating tumor DNA (ctDNA) allowed us to monitor responses to therapy and to identify and then follow mechanisms of resistance. how PDXs can be used to validate hypothesis- driven combination therapies for patients with melanoma. WES of ctDNA could reveal mechanisms of resistance to therapy & make decisions about when to continue and when to withdraw treatment. resistance emerges in the majority of patients on targeted therapies and not all patients respond to immunotherapies, so it is clinically challenging to select patients for these different modalities, to determine when to switch between modalities and to select second-line therapies for patients who fail to respond or who relapse.
  8. https://www.labpulse.com/index.aspx?sec=sup&sub=onc&pag=dis&ItemID=800034 https://www.christie.nhs.uk/media/3756/legacymedia-4159-final_target_poster_asco_2016_final-draft_25-05-16.pdf https://www.precisiononcologynews.com/sequencing/liquid-biopsy-utility-reinforced-early-results-uk-target-program#.Xs96KV0RpN0 on a routine basis, with a data turnaround time compatible with clinical practice and at an affordable cost (approximately £1,600 per patient) that leads to benefit in a proportion of phase I trial patients. The first part of TARGET included 100 patients with 22 different types of solid tumors, the most common of which were colorectal cancer, breast cancer, and non-small cell lung cancer. Participants had received a mean of two prior therapies. The overall intent of TARGET was to develop a robust work- flow supporting clinical decision-making that can be delivered on a routine basis, with a data turnaround time compatible with clinical practice and at an affordable cost.
  9. Not a swift publication, but worth to mention to the customer who want to use 1S kit for cfDNA short fragment retention
  10. Similar to targeted DNA sequencing for somatic variant detection, analyzing a focused set of RNA sequences allows sequencing to greater depth and supports rapid, cost-effective sample processing. Panels with preselected, expert-defined content are available for several areas of interest.
  11. Ribodepletion Workflow Methods 50-100 ng of UHR and FFPE Samples 1-2 were ribodepleted using Lexogen Ribocop4 V1.3 and eluted in 5 L dH2O for input into the Swift RNA Library Kit5. Swift RNA libraries were made with the following adjustments: fragmentation at 65C for 5 min and a 1.2X post-RT SPRI clean-up (see Protocol Considerations below). All libraries were amplified using 12 PCR cycles. Libraries were sequenced on a Miniseq 2 x 75 bp and downsampled to 3 million reads prior to analysis with STAR6, picard7, rnaseqc8, and fgbio9. CDS = coding sequence; UTR = untranslated region (5’ and 3’).
  12. Bioanalyzer date 19.10.11
  13. Adaptase step is a highly efficient, template-independent reaction that simultane-ously performs tailing and ligation of truncated adapter to 3’ ends Extension step is used to incorporate truncated adapter 1 by a primer extension reaction Ligation step is used to add truncated adapter2 to the top/bottom strand only. Index PCR increase yield and incorporates full length adapters for single or dual indexing
  14. Size selection must occur before bisulfite conversion because conversion will fragment DNA, affecting fragment size selection. Improper size selection may affect CpG island coverage.
  15. CCGA: This is a prospective, multi-center, observational study with collection of de-identified biospecimens and clinical data from at least 15,000 participants from clinical networks in the United States and Canada. The study will enroll approximately 10,500 cancer participants (CANCER arm) and approximately 4,500 representative participants without a clinical diagnosis of cancer (NON-CANCER arm). Clinical information, demographics, and medical data relevant to cancer status are collected from all participants and their medical record at baseline (time of biospecimen collection), and subsequently from the medical record at intermittent future time points, at least annually for up to 5 years. The PATHFINDER Study is a prospective, multi-center study that will evaluate the implementation of GRAIL’s multi-cancer early detection test into clinical practice. GRAIL’s test is designed to detect and localize multiple types of cancer through a single blood draw, with a very low false positive rate. PATHFINDER is the first time GRAIL’s multi-cancer early detection test will be used to return results to healthcare providers and communicated to participants to help guide appropriate diagnostic workup for more than 50 cancer types. The study will enroll approximately 6,200 participants, and they will be followed for 12 months from the time of their enrollment. The STRIVE Study is a prospective, observational, longitudinal, cohort study that has enrolled approximately 100,000 women at the time of their screening mammogram. STRIVE will be used to validate a blood test for the early detection of multiple cancer types. Participants completed a health questionnaire and provided a blood sample around the time of their screening mammogram and will be followed for up to five years to capture clinical outcome data, including cancer diagnoses. The SUMMIT Study is a prospective, observational, longitudinal, cohort study being conducted in London in the United Kingdom. It is designed to enroll approximately 50,000 men and women age 50 to 77 years who do not have a cancer diagnosis at the time of enrollment. SUMMIT aims to evaluate a blood test designed to detect multiple types of cancer, including lung cancer. Approximately half the participants will be people at high risk of lung and other cancers due to a significant smoking history, and the other half will be people who are not at high risk for cancer based on smoking history. Participants will be followed annually for three years and then will be followed for five years through national health registries as well as their medical records.
  16. The first sub-study aimed to identify the highest performing assay(s) for further development and included three independent, comprehensive sequencing approaches A methylation-based assay was selected for further development in this second sub-study based on the previous finding that WGBS outperformed targeted sequencing and WGS approaches targeting SNVs/small insertions and deletions and CNVs, respectively. This second sub-study reported herein included 4841 participants from CCGA divided into a training set (n = 3133: 1742 cancer and 1391 non-cancer) and an independent validation set (n =1354: 740 cancer and 614 non-cancer);
  17. In summary, cfDNA sequencing of informative methylation patterns detected a broad range of cancer types at metastatic and non-metastatic stages with specificity and sensitivity performance approaching the goal for population-level screening.
  18. CancerLocator: We propose a probabilistic method, CancerLocator, which exploits the diagnostic potential of cell-free DNA by determining not only the presence but also the location of tumors. CancerLocator simultaneously infers the proportions and the tissue-of-origin of tumor-derived cell-free DNA in a blood sample using genome-wide DNA methylation data. CancerLocator outperforms two established multi-class classification methods on simulations and real data, even with the low proportion of tumor-derived DNA in the cell-free DNA scenarios. CancerLocator also achieves promising results on patient plasma samples with low DNA methylation sequencing coverage. CancerDector: The detection of tumor-derived cell-free DNA in plasma is one of the most promising directions in cancer diagnosis. The major challenge in such an approach is how to identify the tiny amount of tumor DNAs out of total cell-free DNAs in blood. Here we propose an ultrasensitive cancer detection method, termed ‘CancerDetector’, using the DNA methylation profiles of cell-free DNAs. The key of our method is to probabilistically model the joint methylation states of multiple adjacent CpG sites on an individ- ual sequencing read, in order to exploit the perva- sive nature of DNA methylation for signal amplifica- tion. Therefore, CancerDetector can sensitively iden- tify a trace amount of tumor cfDNAs in plasma, at the level of individual reads. We evaluated CancerDetec- tor on the simulated data, and showed a high con- cordance of the predicted and true tumor fraction. Testing CancerDetector on real plasma data demon- strated its high sensitivity and specificity in detecting tumor cfDNAs. In addition, the predicted tumor frac- tion showed great consistency with tumor size and survival outcome. Note that all of those testing were performed on sequencing data at low to medium cov- erage (1× to 10×). Therefore, CancerDetector holds the great potential to detect cancer early and cost- effectively.
  19. A panel can design all bases across the gene or can be focused on specific mutation hotspot. Since genes design relies on tilling overlapping amplicons, if ampliseq want to amplify whole sequence of a gene, regions A &C can be pooled together, but not for region B. As a result, overlapping primers must be separated in different PCR reactions. A mutation hotspot design typically result in un-overlapping amplicons, primers can combined into single-multiplex reaction.
  20. Using OncoKB (oncokb.org), we’ve developed a set of targets for each cancer subtype that are FDA-recognized biomarkers predictive of response to FDA-approved drugs or standard of care biomarkers predicative of response to an FDA-approved drug. In addition, we have completed market research on existing cancer specific panels to guide our development of a list of core targets.
  21. The Accel-Amplicon 56G Oncology Panel v2 offers comprehensive and hotspot coverage of 56 clinically-relevant oncology-related genes. This panel utilizes a 263-amplicon design, covering over 16,000 COSMIC mutations, to generate targeted libraries compatible with Illumina sequencing platforms and now includes 104 exonic and gender Sample_ID amplicons spiked in at a low percentage (2-4% of reads) for tracking tumor-normal pairs and samples in longitudinal studies.
  22. For analysis we have VarSome as you said but also a partnership with Fluxion Biosciences, which allows achieving <1% frequency variant calling from cfDNA using a published error subtraction statistical model called ERASE-seq (PCR and sequencing errors are random, but low frequency variants are real and persist in replicate samples). Fluxion is a great partner of ours and willing to do free proof of concept demos and provide low per sample analysis software. Or we can share with any customer our open source Linux pipeline for free at any time via Docker image / FTP
  23. Unique molecular identifier incorporated into PCR product during first 3 cycles Noise removal reveals true positive variant calls at 0.2% - 1.0% frequency From 10-20 ng DNA to Illumina® library in < 3 hrs > 95% on-target and coverage uniformity from human cfDNA and synthetic cfDNA controls Maximum10-100 amplicons/tube